D 5519

Drug Profile

D 5519

Latest Information Update: 24 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Draco Lakemedel
  • Developer Draco Lakemedel; Nonindustrial source
  • Class Antiasthmatics; Corticosteroids
  • Mechanism of Action Arachidonic acid inhibitors; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Bronchitis; Inflammatory bowel diseases

Most Recent Events

  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
  • 25 Mar 1999 No-Development-Reported for Asthma in Sweden (Inhalation)
  • 25 Mar 1999 No-Development-Reported for Bronchitis in Sweden (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top